
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9191586/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Effectiveness of Perioperative Opioid Educational Initiatives: A Systematic Review and Meta-Analysis. Anesthesia and Analgesia, 2022, 134, 940-951.	2.2	6
2	Open vs minimally invasive radical trachelectomy in early-stage cervical cancer: International Radical Trachelectomy Assessment Study. American Journal of Obstetrics and Gynecology, 2022, 226, 97.e1-97.e16.	1.3	20
3	Employment disruption among women with gynecologic cancers. International Journal of Gynecological Cancer, 2022, 32, 69-78.	2.5	6
4	ls prior conization the way forward to determine surgical approach? The answer is not so simple!. International Journal of Gynecological Cancer, 2022, 32, 125-126.	2.5	1
5	Interviews from the European Society of Gynaecological Oncology 2021 Congress: an IJGC-ENYGO Fellows compilation. International Journal of Gynecological Cancer, 2022, 32, 468-473.	2.5	0
6	Outcomes of open radical hysterectomy following implementation of an enhanced recovery after surgery program. International Journal of Gynecological Cancer, 2022, 32, 480-485.	2.5	2
7	A prospective randomized trial comparing liposomal bupivacaine vs standard bupivacaine wound infiltration in open gynecologic surgery on an enhanced recovery pathway. American Journal of Obstetrics and Gynecology, 2021, 224, 70.e1-70.e11.	1.3	11
8	Fertility considerations prior to conservative management of gynecologic cancers. International Journal of Gynecological Cancer, 2021, 31, 339-344.	2.5	8
9	Impact of anesthesia technique on post-operative opioid use in open gynecologic surgery in an enhanced recovery after surgery pathway. International Journal of Gynecological Cancer, 2021, 31, 569-574.	2.5	4
10	Effect of preoperative intravenous vs oral acetaminophen on postoperative opioid consumption in an enhanced recovery after surgery (ERAS) program in patients undergoing open gynecologic oncology surgery. Gynecologic Oncology, 2021, 160, 464-468.	1.4	13
11	mTOR Pathway Activation Assessed by Immunohistochemistry in Cervical Biopsies of HPV-associated Endocervical Adenocarcinomas (HPVA): Correlation With Silva Invasion Patterns. Applied Immunohistochemistry and Molecular Morphology, 2021, 29, 527-533.	1.2	2
12	Dasatinib, paclitaxel, and carboplatin in women with advanced-stage or recurrent endometrial cancer: A pilot clinical and translational study. Gynecologic Oncology, 2021, 161, 104-112.	1.4	4
13	Technique for inguino-femoral lymph node dissection in vulvar cancer: an international survey. International Journal of Gynecological Cancer, 2021, 31, ijgc-2021-002452.	2.5	1
14	Impact of a tiered discharge opioid algorithm on prescriptions and patient-reported outcomes after open gynecologic surgery. International Journal of Gynecological Cancer, 2021, 31, ijgc-2021-002674.	2.5	4
15	Enhanced recovery after surgery in gynecologic oncology: time to address barriers to implementation in low- and middle-income countries. International Journal of Gynecological Cancer, 2021, 31, 1195-1196.	2.5	4
16	Incidence of acute kidney injury after open gynecologic surgery in an enhanced recovery after surgery pathway. Gynecologic Oncology, 2021, 163, 191-198.	1.4	5
17	Standardizing ovarian cancer surgery and peri-operative care: a European Society of Gynecological Oncology (ESGO) consensus statement. International Journal of Gynecological Cancer, 2021, 31, 1207-1208.	2.5	0
18	Association Between Overall Survival and the Tendency for Cancer Programs to Administer Neoadjuvant Chemotherapy for Patients With Advanced Ovarian Cancer. JAMA Oncology, 2021, 7, 1782.	7.1	21

#	Article	IF	CITATIONS
19	ConCerv: a prospective trial of conservative surgery for low-risk early-stage cervical cancer. International Journal of Gynecological Cancer, 2021, 31, 1317-1325.	2.5	79
20	Minimally invasive radical trachelectomy: Considerations on surgical approach. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2021, 75, 113-122.	2.8	6
21	Determining post-operative morbidity and mortality following gynecological oncology surgery: protocol for a multicenter, international, prospective cohort study (Global Gynaecological) Tj ETQq1 1 0.784 Cancer, 2021, 31, 1287-1291.	314 rgBT /Ov 2.5	erlogk 10 Tf
22	Longitudinal patient-reported outcomes and restrictive opioid prescribing after minimally invasive gynecologic surgery. International Journal of Gynecological Cancer, 2021, 31, 114-121.	2.5	11
23	Paradigm shifts in gynecologic oncology. International Journal of Gynecological Cancer, 2021, 31, ijgc-2021-003108.	2.5	2
24	Bronchocutaneous fistula from metastatic cervical cancer with COVID-19. International Journal of Gynecological Cancer, 2021, 31, 306-306.	2.5	0
25	Impact of implementation of an enhanced recovery program in gynecologic surgery on healthcare costs. American Journal of Obstetrics and Gynecology, 2020, 222, 66.e1-66.e9.	1.3	20
26	Incidence of adverse events in minimally invasive vs open radical hysterectomy in early cervical cancer: results of a randomized controlled trial. American Journal of Obstetrics and Gynecology, 2020, 222, 249.e1-249.e10.	1.3	78
27	Changing treatment landscape for early cervical cancer: outcomes reported with minimally invasive surgery compared with an open approach. Current Opinion in Obstetrics and Gynecology, 2020, 32, 22-27.	2.0	19
28	Tumor size in cervical cancer: an ongoing dilemma. International Journal of Gynecological Cancer, 2020, 30, 1851-1851.	2.5	0
29	Laparoscopic cytoreduction After Neoadjuvant ChEmotherapy (LANCE). International Journal of Gynecological Cancer, 2020, 30, 1450-1454.	2.5	33
30	Measurement of tumor size in early cervical cancer: an ever-evolving paradigm. International Journal of Gynecological Cancer, 2020, 30, 1215-1223.	2.5	26
31	Enhanced recovery for obese patients undergoing gynecologic cancer surgery. International Journal of Gynecological Cancer, 2020, 30, 1595-1602.	2.5	7
32	Quality of life in patients with cervical cancer after open versus minimally invasive radical hysterectomy (LACC): a secondary outcome of a multicentre, randomised, open-label, phase 3, non-inferiority trial. Lancet Oncology, The, 2020, 21, 851-860.	10.7	57
33	Survival After Minimally Invasive vs Open Radical Hysterectomy for Early-Stage Cervical Cancer. JAMA Oncology, 2020, 6, 1019.	7.1	124
34	Revised 2018 International Federation of Gynecology and Obstetrics (FIGO) cervical cancer staging: A review of gaps and questions that remain. International Journal of Gynecological Cancer, 2020, 30, 873-878.	2.5	42
35	Prospective pilot trial with combination of propranolol with chemotherapy in patients with epithelial ovarian cancer and evaluation on circulating immune cell gene expression. Gynecologic Oncology, 2019, 154, 524-530.	1.4	24
36	Conservative management of cervical cancer in pregnancy. International Journal of Gynecological Cancer, 2019, 29, 434-438.	2.5	0

#	Article	IF	CITATIONS
37	Preoperative PET/CT does not accurately detect extrauterine disease in patients with newly diagnosed highâ€risk endometrial cancer: A prospective study. Cancer, 2019, 125, 3347-3353.	4.1	12
38	Adaptive responses in a PARP inhibitor window of opportunity trial illustrate limited functional interlesional heterogeneity and potential combination therapy options. Oncotarget, 2019, 10, 3533-3546.	1.8	19
39	Choosing Wisely: Decreasing the incidence of perioperative blood transfusions in gynecologic oncology. Gynecologic Oncology, 2019, 153, 597-603.	1.4	16
40	Validation and application of a module of the MD Anderson Symptom Inventory for measuring perioperative symptom burden in patients with gynecologic cancer (the MDASI-PeriOp-GYN). Gynecologic Oncology, 2019, 152, 492-500.	1.4	12
41	Guidelines for perioperative care in gynecologic/oncology: Enhanced Recovery After Surgery (ERAS) Society recommendations—2019 update. International Journal of Gynecological Cancer, 2019, 29, 651-668.	2.5	452
42	Patient characteristics and opioid use prior to discharge after open gynecologic surgery in an enhanced recovery after surgery (ERAS) program. Gynecologic Oncology, 2019, 153, 604-609.	1.4	27
43	Reproductive counseling and pregnancy outcomes after radical trachelectomy for early stage cervical cancer. Journal of Gynecologic Oncology, 2019, 30, e45.	2.2	37
44	International radical trachelectomy assessment: IRTA study. International Journal of Gynecological Cancer, 2019, 29, 635-638.	2.5	35
45	Impact of compliance with an enhanced recovery after surgery pathway on patient outcomes in open gynecologic surgery. International Journal of Gynecological Cancer, 2019, 29, 1417-1424.	2.5	31
46	Perineural invasion (PNI) in vulvar carcinoma: A review of 421 cases. Gynecologic Oncology, 2019, 152, 101-105.	1.4	18
47	Determining the Safety and Efficacy of Enhanced Recovery Protocols in Major Oncologic Surgery: An Institutional NSQIP Analysis. Annals of Surgical Oncology, 2019, 26, 782-790.	1.5	12
48	Radical parametrectomy after â€~cut-through' hysterectomy in low-risk early-stage cervical cancer: Time to consider this procedure obsolete. Gynecologic Oncology, 2018, 149, 520-524.	1.4	7
49	Updates on Conservative Management of Endometrial Cancer. Journal of Minimally Invasive Gynecology, 2018, 25, 308-313.	0.6	86
50	The influence of surgeon volume on outcomes after pelvic exenteration for a gynecologic cancer. Journal of Gynecologic Oncology, 2018, 29, e68.	2.2	9
51	Minimally Invasive versus Abdominal Radical Hysterectomy for Cervical Cancer. New England Journal of Medicine, 2018, 379, 1895-1904.	27.0	1,274
52	Simple trachelectomy with pelvic lymphadenectomy as a viable treatment option in pregnant patients with stage IB1 (≥2â€̄cm) cervical cancer: Bridging the gap to fetal viability. Gynecologic Oncology, 2018, 150, 50-55.	1.4	10
53	Impact of body mass index and operative approach on surgical morbidity and costs in women with endometrial carcinoma and hyperplasia. Gynecologic Oncology, 2017, 145, 55-60.	1.4	48
54	Sensitivity and negative predictive value for sentinel lymph node biopsy in women with early-stage cervical cancer. Gynecologic Oncology, 2017, 145, 96-101.	1.4	143

#	Article	IF	CITATIONS
55	A multicenter assessment of the ability of preoperative computed tomography scan and CA-125 to predict gross residual disease at primary debulking for advanced epithelial ovarian cancer. Gynecologic Oncology, 2017, 145, 27-31.	1.4	95
56	Sentinel lymph node mapping in minimally invasive surgery: Role of imaging with color-segmented fluorescence (CSF). Gynecologic Oncology, 2017, 146, 676-677.	1.4	8
57	Enhanced Recovery Program and Length of Stay After Laparotomy on a Gynecologic Oncology Service: A Randomized Controlled Trial. Obstetrics and Gynecology, 2017, 129, 1139-1139.	2.4	12
58	A prospective validation study of sentinel lymph node mapping for high-risk endometrial cancer. Gynecologic Oncology, 2017, 146, 234-239.	1.4	171
59	Role of Fallopian Tubes in the Development of Ovarian Cancer. Journal of Minimally Invasive Gynecology, 2017, 24, 230-234.	0.6	31
60	Molecular Innovations in Sentinel Lymph Node Evaluation: Moving Beyond Radiotracers and Colored Dyes. Journal of Minimally Invasive Gynecology, 2017, 24, 1-2.	0.6	5
61	Laparoscopic Resection of Pelvic Sidewall Recurrent Cervical Cancer: Feasibility Does Not Always Equate with Clinical Indication. Journal of Minimally Invasive Gynecology, 2017, 24, 881.	0.6	1
62	Bowel injury in robotic gynecologic surgery: riskÂfactors and management options. AÂsystematic review. American Journal of Obstetrics and Gynecology, 2017, 216, 10-26.	1.3	25
63	Survival of patients with metastatic leiomyosarcoma: the MD Anderson Clinical Center for targeted therapy experience. Cancer Medicine, 2016, 5, 3437-3444.	2.8	20
64	Outpatient laparoscopic nerve-sparing radical hysterectomy: A feasibility study and analysis of perioperative outcomes. Gynecologic Oncology, 2016, 143, 352-356.	1.4	20
65	Utility of indocyanine green (ICG) intra-operative angiography to determine uterine vascular perfusion at the time of radical trachelectomy. Gynecologic Oncology, 2016, 143, 357-361.	1.4	25
66	Role of cervical cytology in surveillance after radical trachelectomy for cervical cancer. Gynecologic Oncology, 2016, 142, 283-285.	1.4	11
67	Long-term outcomes of sentinel node mapping in vulvar cancer: A time to cheer with enthusiasm or pause and question current practice?. Gynecologic Oncology, 2016, 140, 1-2.	1.4	10
68	A call for new standard of care in perioperative gynecologic oncology practice: Impact of enhanced recovery after surgery (ERAS) programs. Gynecologic Oncology, 2016, 141, 371-378.	1.4	118
69	Role of Indocyanine Green in Sentinel Node Mapping in Gynecologic Cancer: Is Fluorescence Imaging the New Standard?. Journal of Minimally Invasive Gynecology, 2016, 23, 186-193.	0.6	47
70	Clinical impact of selective and nonselective betaâ€blockers on survival in patients with ovarian cancer. Cancer, 2015, 121, 3444-3451.	4.1	157
71	Immediate radical trachelectomy versus neoadjuvant chemotherapy followed by conservative surgery for patients with stage IB1 cervical cancer with tumors 2cm or larger: A literature review and analysis of oncological and obstetrical outcomes. Gynecologic Oncology, 2015, 137, 574-580.	1.4	65
72	High-Grade Cervical Dysplasia following Radiation Therapy for Invasive Cervical Cancer: A Report of Four Cases. Case Reports in Oncology, 2015, 8, 217-221.	0.7	3

#	Article	IF	CITATIONS
73	Radiotherapy for recurrent small cell carcinoma of the ovary: A case report and review of the literature. Gynecologic Oncology Reports, 2015, 11, 23-25.	0.6	18
74	The role of secondary cytoreduction in low-grade serous ovarian cancer or peritoneal cancer. Gynecologic Oncology, 2015, 136, 25-29.	1.4	51
75	Laparoscopic Supracervical Hysterectomy With Morcellation: Should It Stay or Should It Go?. Journal of Minimally Invasive Gynecology, 2015, 22, 185-192.	0.6	20
76	Improvement in quality of life after robotic surgery results in patient satisfaction. Gynecologic Oncology, 2015, 138, 727-730.	1.4	20
77	Radical trachelectomy in early-stage cervical cancer: A comparison of laparotomy and minimally invasive surgery. Gynecologic Oncology, 2015, 138, 585-589.	1.4	86
78	Ovarian Torsion After Laparoscopic Ovarian Transposition in Patients With Gynecologic Cancer: A Report of Two Cases. Journal of Minimally Invasive Gynecology, 2015, 22, 687-690.	0.6	19
79	Perioperative trajectory of patient reported symptoms: A pilot study in gynecologic oncology patients. Gynecologic Oncology, 2015, 136, 440-445.	1.4	22
80	Predictors of optimal cytoreduction in patients with newly diagnosed advanced-stage epithelial ovarian cancer: Time to incorporate laparoscopic assessment into the standard of care. Gynecologic Oncology, 2015, 137, 553-558.	1.4	69
81	Clinical outcomes in patients with isolated serous tubal intraepithelial carcinoma (STIC): A comprehensive review. Gynecologic Oncology, 2015, 139, 568-572.	1.4	69
82	Sustained Complete Response after Maintenance Therapy with Topotecan and Erlotinib for Recurrent Cervical Cancer with Distant Metastases. Case Reports in Oncology, 2014, 7, 97-101.	0.7	3
83	Uterine adenosarcoma: An analysis on management, outcomes, and risk factors for recurrence. Gynecologic Oncology, 2014, 135, 455-461.	1.4	84
84	Position-related injury is uncommon in robotic gynecologic surgery. Gynecologic Oncology, 2014, 135, 534-538.	1.4	23
85	Clinically significant endometrial cancer risk following a diagnosis of complex atypical hyperplasia. Gynecologic Oncology, 2014, 135, 451-454.	1.4	37
86	A case for caution in the pursuit of the sentinel node in women with endometrial carcinoma. Gynecologic Oncology, 2014, 132, 275-279.	1.4	25
87	Conversion from robotic surgery to laparotomy: A case–control study evaluating risk factors for conversion. Gynecologic Oncology, 2014, 134, 238-242.	1.4	19
88	Overall survival after pelvic exenteration for gynecologic malignancy. Gynecologic Oncology, 2014, 134, 546-551.	1.4	84
89	Management of low-risk early-stage cervical cancer: Should conization, simple trachelectomy, or simple hysterectomy replace radical surgery as the new standard of care?. Gynecologic Oncology, 2014, 132, 254-259.	1.4	172
90	A comparison of extraperitoneal versus transperitoneal laparoscopic or robotic para-aortic lymphadenectomy for staging of endometrial carcinoma. Gynecologic Oncology, 2014, 132, 366-371.	1.4	56

#	Article	IF	CITATIONS
91	Invasive extramammary Paget's disease of the bladder diagnosed 18years after noninvasive extramammary Paget's disease of the vulva. Gynecologic Oncology Case Reports, 2014, 8, 27-29.	0.9	7
92	Utility of 18F-FDG PET/CT in follow-up of patients with low-grade serous carcinoma of the ovary. Gynecologic Oncology, 2014, 133, 100-104.	1.4	22
93	Physician pain and discomfort during minimally invasive gynecologic cancer surgery. Gynecologic Oncology, 2014, 134, 243-247.	1.4	45
94	Pelvic exenteration: Impact of age on surgical and oncologic outcomes. Gynecologic Oncology, 2014, 132, 114-118.	1.4	27
95	Surgical, oncological, and obstetrical outcomes after abdominal radical trachelectomy — A systematic literature review. Gynecologic Oncology, 2013, 131, 77-82.	1.4	136
96	Venous Thromboembolic Events in Minimally Invasive Gynecologic Surgery. Journal of Minimally Invasive Gynecology, 2013, 20, 766-769.	0.6	30
97	Extragastrointestinal stromal tumor in the rectovaginal septum in an adolescent. Gynecologic Oncology Case Reports, 2013, 5, 67-69.	0.9	7
98	Extensive cutaneous metastases of ovarian cancer after prolonged response to liposomal doxorubicin. Gynecologic Oncology Case Reports, 2013, 5, 64-66.	0.9	5
99	Impact of surgeon volume on patient safety in laparoscopic gynecologic surgery. Gynecologic Oncology, 2012, 125, 241-244.	1.4	11